Relay Therapeutics Inc
RLAY
查看详细走势图
9.600USD
-0.520-5.14%
收盘 03/27, 16:00（美东）报价延迟15分钟
834.01M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.14%
5天
-3.13%
1月
-6.43%
6月
+85.69%
今年开始到现在
+13.48%
1年
+252.94%
查看详细走势图
TradingKey Relay Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Relay Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名31/391位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价17.09。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Relay Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Relay Therapeutics Inc亮点
亮点风险
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
业绩增长期
公司处于发展阶段，最新年度总收入15.36M美元
估值低估
公司最新PE估值-5.96，处于3年历史低位
机构减仓
最新机构持股170.00M股，环比减少20.23%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值84.16K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.27
分析师目标
根据
12
位分析师
强力买入
评级
17.091
目标均价
+68.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Relay Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Relay Therapeutics Inc简介
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
公司代码RLAY
公司Relay Therapeutics Inc
CEOPatel (Sanjiv K)
网址https://relaytx.com/
相关品种
